Towards Healthcare
Bacteriophage Market Size Expands USD 124.09 Million by 2034

Bacteriophage Market Opportunities and Top Key Players

Based on market forecasts, the bacteriophage sector will expand from USD 55.35 million in 2024 to USD 124.09 million by 2034, experiencing a CAGR of 8.44%. The increasing incidence of antimicrobial resistance and the rising prevalence of infectious diseases bolster market growth. The availability of state-of-the-art research and development facilities and the growing demand for personalized medicines contribute to North America’s dominance.

Content

  • Insight Code: 5773
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

With a bacteriophage market size of USD 124.09 million by 2034 and a CAGR of 8.44%

AI is revolutionizing the bacteriophage space by enhancing phage-host interaction prediction, automating genome editing, and accelerating drug discovery.

While North America dominates due to advanced infrastructure and government support, Asia-Pacific is the fastest-growing region, driven by rising infectious disease prevalence, increasing healthcare spending, and strong public health initiatives

The phage probiotics segment is expected to grow at the highest CAGR, driven by increasing demand for gut health solutions.

Major challenges include host-specificity limitations and phage resistance development.

Strategic collaborations, such as the PHAXIAM-Technophage and NexaBiome-JAFRAL partnerships, are critical for scaling manufacturing, GMP compliance, and clinical trial acceleration

The regulatory environment is still evolving and fragmented. While the FDA and EMA are evaluating frameworks for phage therapies, regulatory clarity is lacking in many regions.
Any Questions